An interventional study of Low-intensity focused ultrasound (LIFU) targeting the left stellate ganglion and Sham low-intensity focused ultrasound targeting the left stellate ganglion in Atrial Fibrillation (AF) and Cardiovascular Diseases, sponsored by Renmin Hospital of Wuhan University. Recruiting at 7 sites in China. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by Renmin Hospital of Wuhan University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 377 studies in Atrial Fibrillation with a site in China — 162 open to participants now, 183 under way, 4 of them phase 3. Atrial Fibrillation · China.
Among the 377 studies in Atrial Fibrillation with a site in China, this one is the 139th largest by planned enrollment of the 256 interventional ones that give a count, is one of 48 that started in 2026, is one of 200 with no phase, reaches primary completion later than 105 of the 182 other live ones, and was the 345th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →162 of the 377 studies in Atrial Fibrillation with a site in China are open now. Recruiting first, the newest first:
Biosense Webster, Inc. · Sites in China
Ages 18–80
Johnson & Johnson Medical (Shanghai) Ltd. · Sites in China
Ages 18–80
China National Center for Cardiovascular Diseases · Sites in China
Ages 18–75
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
Peking Union Medical College Hospital · Sites in China
Ages 60+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
377 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 20 · Phase 4 28
First in 2005; this study’s year is marked. 48 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 235 across the 256 interventional studies, 500 across the 121 observational. Of the 110 that completed or were terminated, 24 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
71 of 377 have an industry lead sponsor. The 10 most frequent:
Renmin Hospital of Wuhan University is the lead sponsor of 86 studies on the registry; 29 are open to participants now.
Renmin Hospital of Wuhan University has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
50 of the studies in Atrial Fibrillation with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT06722196Phase 3Jilin Heart HospitalBiodEgradable Soaked Amiodarone paTch Use for the Prevention of Atrial Fibrillation After Cardiac Surgery | 2027-01-15 |
| NCT06125925The First Affiliated Hospital with Nanjing Medical UniversityCatheter Ablation in Atrial Fibrillation Patients With HFpEF (STABLE-SR IV Trial) | 2026-11 |
| NCT07139314Capital Medical UniversityTiming of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation 2 | 2026-11-30 |
| NCT07541339Beijing Anzhen HospitalSafety and Efficacy of Conscious Sedation Versus General Anesthesia in Pulsed-Field Ablation for Paroxysmal Atrial Fibrillation | 2026-12-01 |
Add all 50 to your calendar (.ics) → With an account.
Among the 377 studies in Atrial Fibrillation with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this multicenter, double-blind, randomized controlled trial is to evaluate the efficacy and safety of low-intensity focused ultrasound (LIFU) stellate ganglion modulation for improving autonomic function and sleep quality in perioperative cardiovascular disease patients.
The main questions it aims to answer are:
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in this arm will receive low-intensity focused ultrasound (LIFU) intervention on the left stellate ganglion. Ultrasound parameters: power 2.0 W, frequency 1 MHz, 50% duty cycle, 30 minutes per session, once daily for 3-7 consecutive days. All subjects will receive guideline-concordant standard perioperative cardiovascular care, including surgery and indicated medications.
Device: Low-intensity focused ultrasound (LIFU) targeting the left stellate ganglion
Subjects in this arm will receive sham ultrasound intervention with identical operational procedures, device appearance, and parameter settings (no actual energy output) as the intervention arm. Sessions are once daily for 3-7 consecutive days. All subjects will receive the same guideline-concordant standard perioperative cardiovascular care as the intervention arm.
Device: Sham low-intensity focused ultrasound targeting the left stellate ganglion
The experimental group receives active low-intensity focused ultrasound (LIFU) treatment: the ultrasound probe is placed on the skin surface corresponding to the left stellate ganglion and fixed with a mechanical arm, with parameters set as power 2.0W, frequency 1MHz, duty cycle 50%, 30 minutes per session, once daily for 3-7 consecutive days. All enrolled subjects receive standard perioperative cardiovascular care simultaneously throughout the study period.
The control group receives sham low-intensity focused ultrasound intervention: the ultrasound probe is placed on the skin surface corresponding to the left stellate ganglion and fixed with a mechanical arm, with the same instrument appearance, operation process, parameter setting display (power 2.0W, frequency 1MHz, duty cycle 50%), duration (30 minutes per session, once daily for 3-7 consecutive days) and subject experience as the experimental group, but no actual ultrasound energy is output. All enrolled subjects receive standard perioperative cardiovascular care simultaneously throughout the study period.
SDNN
Standard deviation of all normal-to-normal intervals measured by wearable Holter monitor; Unit: ms; Measurement device: wearable Holter monitors.
Time frame: Pre-operative 24 hours and Post-operative 72 hours
Total sleep duration
Total sleep time measured by wearable sleep monitor; Unit: hours; Measurement device: Wearable sleep monitor.
Time frame: Pre-operative 24 hours and Post-operative 72 hours
SDANN
Standard deviation of the averages of NN intervals in all 5-minute segments; Unit: ms; Measurement device: wearable Holter monitors.
Time frame: Pre-operative 24 hours and Post-operative 72 hours
SDNN Index
Mean of the standard deviations of all NN intervals for all 5-minute segments; Unit: ms; Measurement device: wearable Holter monitors.
Time frame: Pre-operative 24 hours and Post-operative 72 hours
RMSSD
Root mean square of successive differences between normal heartbeats; Unit: ms; Measurement device: wearable Holter monitors.
Time frame: Pre-operative 24 hours and Post-operative 72 hours
pNN50
Percentage of successive NN intervals that differ by more than 50 ms; Unit: %; Measurement device: wearable Holter monitors.
Time frame: Pre-operative 24 hours and Post-operative 72 hours
LF power
Low frequency power of heart rate variability; Unit: ms²; Measurement device: wearable Holter monitors.
Time frame: Pre-operative 24 hours and Post-operative 72 hours
HF power
High frequency power of heart rate variability; Unit: ms²; Measurement device: wearable Holter monitors.
Time frame: Pre-operative 24 hours and Post-operative 72 hours
TP
Total power of heart rate variability; Unit: ms²; Measurement device: wearable Holter monitors.
Time frame: Pre-operative 24 hours and Post-operative 72 hours
LF/HF ratio
Ratio of low frequency to high frequency power; Unit: ratio; Measurement device: wearable Holter monitors.
Time frame: Pre-operative 24 hours and Post-operative 72 hours
Wakefulness percentage
Percentage of time awake during sleep period; Unit: %; Measurement device: Wearable sleep monitor.
Time frame: Pre-operative 24 hours and Post-operative 72 hours
Insomnia percentage
Percentage of time with insomnia symptoms during sleep period; Unit: %; Measurement device: Wearable sleep monitor.
Time frame: Pre-operative 24 hours and Post-operative 72 hours
REM sleep percentage
Percentage of rapid eye movement sleep during total sleep time; Unit: %; Measurement device: Wearable sleep monitor.
Time frame: Pre-operative 24 hours and Post-operative 72 hours
N1 sleep stage percentage
Percentage of N1 sleep stage during total sleep time; Unit: %; Measurement device: Wearable sleep monitor.
Time frame: Pre-operative 24 hours and Post-operative 72 hours
N2 and N3 sleep stages percentage
Combined percentage of N2 and N3 sleep stages during total sleep time; Unit: %; Measurement device: Wearable sleep monitor.
Time frame: Pre-operative 24 hours and Post-operative 72 hours
Sleep efficiency
Ratio of total sleep time to time in bed; Unit: %; Measurement device: Wearable sleep monitor.
Time frame: Pre-operative 24 hours and Post-operative 72 hours
IL-1β level
Serum IL-1β concentration; Unit: pg/mL.
Time frame: Pre-operative 24 hours and Post-operative 72 hours
Norepinephrine (NE) level
Serum norepinephrine concentration; Unit: pg/mL.
Time frame: Pre-operative 24 hours and Post-operative 72 hours
Brain-derived neurotrophic factor (BDNF) level
Serum brain-derived neurotrophic factor concentration; Unit: pg/mL.
Time frame: Pre-operative 24 hours and Post-operative 72 hours
Pittsburgh Sleep Quality Index (PSQI) score
Subjective sleep quality assessed using the Pittsburgh Sleep Quality Index questionnaire; Unit: Score on a 0-21 scale, where higher scores indicate worse sleep quality; Method of Measurement: Self-administered questionnaire.
Time frame: Pre-operative 24 hours and Post-operative 72 hours
Number of atrial arrhythmias
Measurement: count of atrial arrhythmia episodes. Measurement device: wearable Holter monitors.
Time frame: Pre-operative 24 hours and Post-operative 72 hours
Duration of atrial arrhythmias
Measurement: Duration of atrial arrhythmia episodes. Measurement device: wearable Holter monitors.
Time frame: Pre-operative 24 hours and Post-operative 72 hours
TNF-α level
Serum TNF-α concentration; Unit: pg/mL.
Time frame: Pre-operative 24 hours and Post-operative 72 hours
Neuropeptide Y (NPY) level
Serum neuropeptide Y concentration; Unit: pg/mL.
Time frame: Pre-operative 24 hours and Post-operative 72 hours
Melatonin level
Serum melatonin concentration; Unit: pg/mL.
Time frame: Pre-operative 24 hours and Post-operative 72 hours
Plan to share: Undecided — Due to considerations for protecting participant privacy, undetermined data ownership, or the absence of a detailed data-sharing policy.
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Apr 2027, 10 months after the start.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 10 months is below that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renmin Hospital of Wuhan University